LONDON, April 25 (Reuters)- GlaxoSmithKline's new shingles vaccine Shingrix exceeded expectations in the first quarter, but the drugmaker's sales and earnings fell 2 percent, held back by a stronger pound and more pricing pressure in respiratory medicine. (cnbc.com)
GlaxoSmithKline's new shingles vaccine Shingrix exceeded expectations in the first quarter, but the drugmaker's sales and earnings fell 2 percent, held back by a stronger pound and more pricing pressure in respiratory medicine. (cnbc.com)
GlaxoSmithKline wins FDA approval of next - gen shingles vaccine. (fortune.com)